Candido E. Rivera, M.D.

  1. Hematologist
  2. Internist
  3. Oncologist
  1. Abdelmagid MG, Al-Kali A, Litzow MR, Begna KH, Hogan WJ, Patnaik MS, Hashmi SK, Elliott MA, Alkhateeb H, Karrar OS, Fleti F, Elnayir MH, Rivera CE, Murthy HS, Foran JM, Kharfan-Dabaja MA, Badar T, Viswanatha DS, Reichard KK, Gangat N, Tefferi A. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events. Blood Cancer J. 2023 Aug 11; 13 (1):122
    View PubMed
  2. Wolf EB, Li D, Fernandez AJ, Gardner LB, Rivera CE, Wysokinska EM, Shaikh ME, Tun HW, Roy V, Alhaj Moustafa M. Acquired Factor VII Deficiency Associated With Chronic Myeloid Leukemia Blast Crisis. J Investig Med High Impact Case Rep. 2023 Jan-Dec; 11:23247096231209543.
    View PubMed
  3. Fortich S, Ritchie C, Shaikh ME, Toskich B, Rivera CE, Erben Y. Deep vein thrombosis in the setting of Klippel-Trenaunay syndrome and sirolimus treatment. J Vasc Surg Cases Innov Tech. 2021 Sep; 7 (3):524-528 Epub 2021 July 17
    View PubMed
  4. Bansal P, Yarrarapu S, Abia D, Cusik A, Melody ME, Moktan VP, Rivero A, Brigham T, Libertin CR, Brumble L, OBrien J, Lee AS, Torp KD, Santos CD, Rivera CE, Siegel J, Guru PK, Moreno P, Sanghavi DK. V.I.T.A.M. in COVID 19: A systematic approach to a global pandemic Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine. 2021.
  5. McBane RD 2nd, Torres Roldan VD, Niven AS, Pruthi RK, Franco PM, Linderbaum JA, Casanegra AI, Oyen LJ, Houghton DE, Marshall AL, Ou NN, Siegel JL, Wysokinski WE, Padrnos LJ, Rivera CE, Flo GL, Shamoun FE, Silvers SM, Nayfeh T, Urtecho M, Shah S, Benkhadra R, Saadi SM, Firwana M, Jawaid T, Amin M, Prokop LJ, Murad MH. Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic. Mayo Clin Proc. 2020 Nov; 95 (11):2467-2486 Epub 2020 Aug 31
    View PubMed
  6. Oh ST, Talpaz M, Gerds AT, Gupta V, Verstovsek S, Mesa R, Miller CB, Rivera CE, Fleischman AG, Goel S, Heaney ML, O'Connell C, Arcasoy MO, Zhang Y, Kawashima J, Ganz T, Kowalski M, Brachmann CB. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020 Sep 22; 4 (18):4282-4291
    View PubMed
  7. Bubik RJ, Barth DM, Hook C, Wolf RC, Muth JM, Mara K, Patnaik MS, Pruthi RK, Marshall AL, Litzow MR, Elliott MA, Hogan WJ, Shah MV, Begna KH, Alkhateeb H, Pardanani A, Ashrani AA, Call TG, Rivera CE, Camoriano JK, Go RS, Wolanskyj-Spinner AP, Parikh SA. Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. Leuk Lymphoma. 2020 Jul; 61 (7):1592-1600 Epub 2020 Mar 11
    View PubMed
  8. Hammond WA, Vishnu P, Rodriguez EM, Li Z, Dholaria B, Shreders AJ, Rivera CE. Sequence of Splenectomy and Rituximab for the Treatment of Steroid-Refractory Immune Thrombocytopenia: Does It Matter? Mayo Clin Proc. 2019 Nov; 94 (11):2199-2208
    View PubMed
  9. Palmer WC, Vishnu P, Sanchez W, Aqel B, Riegert-Johnson D, Seaman LAK, Bowman AW, Rivera CE. Diagnosis and Management of Genetic Iron Overload Disorders. J Gen Intern Med. 2018 Dec; 33 (12):2230-2236 Epub 2018 Sept 17
    View PubMed
  10. Castellino A, Chiappella A, LaPlant BR, Pederson LD, Gaidano G, Macon WR, Inghirami G, Reeder CB, Tucci A, King RL, Congiu A, Foran JM, Pavone V, Rivera CE, Spina M, Ansell SM, Cavallo F, Molinari AL, Ciccone G, Habermann TM, Witzig TE, Vitolo U, Nowakowski GS. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. Blood Cancer J. 2018 Nov 8; 8 (11):108 Epub 2018 Nov 08
    View PubMed
  11. Vishnu P, Moreno Vanegas Y, Wadei HM, Rivera CE. Post-transplant erythrocytosis refractory to ACE inhibitors and angiotensin receptor blockers. BMJ Case Rep. 2018 Jun 28; 2018.
    View PubMed
  12. Baldeo CM, Rivera CE, Tun HW, Vishnu P. Pharmacokinetics-based clinical management of acquired von Willebrand syndrome: a case report. J Blood Med. 2018; 9:9-13 Epub 2018 Jan 19
    View PubMed
  13. Gupta V, Mesa RA, Deininger MW, Rivera CE, Sirhan S, Brachmann CB, Collins H, Kawashima J, Xin Y, Verstovsek S. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica. 2017 Jan; 102 (1):94-102 Epub 2016 Sept 15
    View PubMed
  14. Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Gonsalves W, Witzig TE, Ailawadhi S, Dingli D, Go RS, Lin Y, Rivera CE, Rajkumar SV, Lacy MQ. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood. 2016 Nov 17; 128 (20):2415-2422 Epub 2016 Oct 04
    View PubMed
  15. Blackshear JL, McRee CW, Safford RE, Pollak PM, Stark ME, Thomas CS, Rivera CE, Wysokinska EM, Chen D. von Willebrand Factor Abnormalities and Heyde Syndrome in Dysfunctional Heart Valve Prostheses. JAMA Cardiol. 2016 May 1; 1 (2):198-204
    View PubMed
  16. Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015 Aug 14; 5:e338
    View PubMed
  17. Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol. 2015 Jan 20; 33 (3):251-7 Epub 2014 Aug 18
    View PubMed
  18. Scott KM, Gardner FP, Eidelman BH, Rivera CE, Menke DM, Barrett KM. Clinical reasoning: a 69-year-old man with leukocytosis and hemorrhagic brain lesions. Neurology. 2014 Jul 1; 83 (1):e1-5
    View PubMed
  19. Tefferi A, Hudgens S, Mesa R, Gale RP, Verstovsek S, Passamonti F, Cervantes F, Rivera C, Tencer T, Khan ZM. Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clin Ther. 2014 Apr 1; 36 (4):560-6 Epub 2014 Mar 14
    View PubMed
  20. Paulus A, Masood A, Miller KC, Khan AN, Akhtar D, Advani P, Foran J, Rivera C, Roy V, Colon-Otero G, Chitta K, Chanan-Khan A. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. Br J Haematol. 2014 Apr; 165: (1)78-88.
    View PubMed
  21. Paulus A, Chitta K, Akhtar S, Personett D, Miller KC, Thompson KJ, Carr J, Kumar S, Roy V, Ansell SM, Mikhael JR, Dispenzieri A, Reeder CB, Rivera CE, Foran J, Chanan-Khan A. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia. Br J Haematol. 2014 Feb; 164 (3):352-365 Epub 2013 Nov 17
    View PubMed
  22. Peterson JL, Hayostek CJ, Garvey C, Menke DM, Rivera CE. Hodgkin lymphoma of the maxillary sinus: an unusual occurrence. Ear Nose Throat J. 2012 Jan; 91 (1):E16-9
    View PubMed
  23. Nowakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Klebig RR, Reeder CB, Witzig TE. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia. 2011 Dec; 25 (12):1877-81 Epub 2011 July 01
    View PubMed
  24. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20; 27 (27):4563-9 Epub 2009 Aug 03
    View PubMed
  25. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009 Sep; 33 (9):1199-203 Epub 2009 Feb 27
    View PubMed
  26. Zubair AC, Grant R, Wu W, Tun H, Rivera C, Moreno-Aspitia A, Joyce M, Roy V, Colon-Otero G, Solberg LA. Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients. Transfusion. 2008 Jun; 48 (6):1106-14 Epub 2008 Feb 25
    View PubMed
  27. Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE, Erlichman C, Wright J, Pardanani A, Lasho T, Finke C, Li CY, Tefferi A. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia. 2007 Sep; 21(9):1964-70. Epub 2007 Jun 21.
    View PubMed
  28. Takahashi Y, McCoy JP Jr, Carvallo C, Rivera C, Igarashi T, Srinivasan R, Young NS, Childs RW. In vitro, vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation. Blood. 2004 Feb 15; 103(4):1383-90.
    View PubMed
  29. Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, Willie G, Ellahham S, Quyyumi AA. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol. 2002 Oct 2; 40(7):1232-40.
    View PubMed
  30. Maciejewski JP, Follmann D, Nakamura R, Saunthararajah Y, Rivera CE, Simonis T, Brown KE, Barrett JA, Young NS. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood. 2001 Dec 15; 98(13):3513-9.
    View PubMed
  31. Maciejewski JP, Rivera C, Kook H, Dunn D, Young NS. Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones. Br J Haematol. 2001 Dec; 115(4):1015-22.
    View PubMed
  32. Falik-Zaccai TC, Anikster Y, Rivera CE, Horne MK 3rd, Schliamser L, Phornphutkul C, Attias D, Hyman T, White JG, Gahl WA. A new genetic isolate of gray platelet syndrome (GPS): clinical, cellular, and hematologic characteristics. Mol Genet Metab. 2001 Nov; 74(3):303-13.
    View PubMed
  33. Rivera CE, Villagra J, Riordan M, Williams S, Lindstrom KJ, Rick ME. Identification of a new mutation in platelet glycoprotein IX (GPIX) in a patient with Bernard-Soulier syndrome. Br J Haematol. 2001 Jan; 112(1):105-8.
    View PubMed
  34. Ikonomi P, Rivera CE, Riordan M, Washington G, Schechter AN, Noguchi CT. Overexpression of GATA-2 inhibits erythroid and promotes megakaryocyte differentiation. Exp Hematol. 2000 Dec; 28(12):1423-31.
    View PubMed
  35. Jones K, Rivera C, Sgadari C, Franklin J, Max EE, Bhatia K, Tosato G. Infection of human endothelial cells with Epstein-Barr virus. J Exp Med. 1995 Nov 1; 182(5):1213-21.
    View PubMed